Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Denileukin diftitox - Eisai

Drug Profile

Denileukin diftitox - Eisai

Alternative Names: DAB389IL-2; DAB389 interleukin-2; E7272; E7777; Interleukin-2 fusion toxin; LY 335348; ONTAK

Latest Information Update: 14 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ajinomoto; Japanese Foundation for Cancer Research
  • Developer Eisai Co Ltd; TSD Japan
  • Class ADP ribose transferases; Antineoplastics; Bacterial toxins; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T-cell lymphoma
  • Phase II Malignant melanoma; Peripheral T-cell lymphoma
  • Discontinued Alopecia; Atopic dermatitis; HIV infections; Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 22 Feb 2019 Denileukin diftitox is still in phase II trials for Cutaneous T-cell lymphoma and Peripheral T-cell lymphoma (Second-line therapy or greater) in Japan (NCT02676778)
  • 24 Jun 2018 Biomarkers information updated
  • 31 Mar 2016 Dr. Reddy's acquires the rights to develop and commercialise denileukin diftitox worldwide, excluding Asia and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top